Health CarePharmaceuticals and Biotechnology
  • Price (USD)158.70
  • Today's Change0.265 / 0.17%
  • Shares traded196.78k
  • 1 Year change+35.76%
  • Beta0.6615
Data delayed at least 15 minutes, as of Nov 29 2022 14:46 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

AbbVie Inc. is a research-based biopharmaceutical company, which is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta; aesthetics products that include Botox Cosmetic, Juvederm Collection and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products consists of Lumigan, Alphagan and Restasis; women's health products include Lo Loestrin, Orilissa and others; and other products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. Its products are sold to wholesalers, government agencies, health care facilities and independent retailers. It also discovers and develop antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).

  • Revenue in USD (TTM)57.82bn
  • Net income in USD13.34bn
  • Incorporated2012
  • Employees50.00k
  • Location
    Abbvie Inc1 N Waukegan RdNORTH CHICAGO 60064United StatesUSA
  • Phone+1 (847) 932-7900
  • Fax+1 (302) 655-5049
  • Websitehttps://www.abbvie.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ABBV:NYQ since
DJS Antibodies LtdDeal completed20 Oct 202220 Oct 2022Deal completed10.87%255.00m
iSTAR Medical SAAnnounced20 Jul 202220 Jul 2022Announced5.98%475.00m
Syndesi Therapeutics SADeal completed01 Mar 202201 Mar 2022Deal completed7.39%1.00bn
Data delayed at least 15 minutes, as of Nov 29 2022 14:46 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Amgen, Inc.26.33bn6.84bn150.80bn24.20k22.6441.2814.795.7312.4812.4848.096.850.40921.435.221,088,017.0010.6211.0713.7413.4075.7879.2925.9630.881.357.700.913849.282.182.47-18.87-5.261.0111.97
Bristol-Myers Squibb Co46.74bn6.68bn168.26bn32.20k25.805.159.883.603.073.0721.5315.380.44714.655.721,451,491.006.402.677.943.2978.9174.1814.326.541.314.490.5443163.849.0919.01177.589.43-4.355.22
Merck & Co Inc58.97bn15.32bn274.96bn68.00k17.976.1814.334.666.046.0123.2317.550.5883.066.53867,264.7015.297.6119.9510.1470.8570.9226.0016.061.2210.490.405986.0617.314.12173.1825.7922.487.49
Pfizer Inc.99.68bn30.23bn278.25bn79.00k9.403.007.932.795.275.1917.3716.510.53233.797.131,261,722.0016.156.6221.018.2565.5174.0430.3521.321.3716.560.28375.7295.169.00238.0525.516.285.39
AbbVie Inc57.82bn13.34bn280.18bn50.00k21.1117.5212.914.857.517.5132.549.040.39855.325.771,156,380.009.257.4611.739.4671.1672.0323.2118.110.83138.810.812897.8922.6916.99151.7114.1310.4417.93
Eli Lilly And Co29.24bn6.03bn347.55bn35.00k54.9734.5145.5711.896.656.6532.2710.600.61141.844.63835,414.3012.6211.0818.2815.8075.6177.1620.6320.770.88228.190.609853.7515.405.94-9.8815.3111.4010.76
Data as of Nov 29 2022. Currency figures normalised to Abbvie Inc's reporting currency: US Dollar USD

Institutional shareholders

30.16%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 2022148.48m8.40%
BlackRock Fund Advisorsas of 30 Sep 202285.68m4.85%
SSgA Funds Management, Inc.as of 30 Sep 202277.49m4.38%
Capital Research & Management Co. (International Investors)as of 30 Sep 202245.83m2.59%
JPMorgan Investment Management, Inc.as of 30 Sep 202241.38m2.34%
Capital Research & Management Co. (Global Investors)as of 30 Sep 202236.19m2.05%
Geode Capital Management LLCas of 30 Sep 202233.83m1.91%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 202224.52m1.39%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 202221.85m1.24%
Norges Bank Investment Managementas of 31 Dec 202117.97m1.02%
More ▼
Data from 31 Dec 2021 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.